| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERN.13.39 |
| P698 | PubMed publication ID | 23621307 |
| P50 | author | Miguel Medina | Q37835217 |
| P2093 | author name string | Jesús Avila | |
| P2860 | cites work | Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. | Q53286286 |
| Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese. | Q53317880 | ||
| Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. | Q53377091 | ||
| Alzheimer's Disease | Q22248111 | ||
| Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior | Q24645994 | ||
| Transmission and spreading of tauopathy in transgenic mouse brain | Q24651334 | ||
| GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers | Q24654145 | ||
| Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo | Q24685647 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| GSK3B polymorphisms alter transcription and splicing in Parkinson's disease | Q28116939 | ||
| A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health | Q28118906 | ||
| Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells | Q28118982 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo | Q28131779 | ||
| GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides | Q28205921 | ||
| Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion | Q28212711 | ||
| TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth | Q28262401 | ||
| Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain | Q28269707 | ||
| LTP inhibits LTD in the hippocampus via regulation of GSK3beta | Q28290606 | ||
| GSK-3beta is required for memory reconsolidation in adult brain | Q28473886 | ||
| PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations | Q28587440 | ||
| Alzheimer's disease is a synaptic failure | Q29547670 | ||
| A beta oligomers - a decade of discovery | Q29615152 | ||
| Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling | Q29977753 | ||
| Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium | Q30362607 | ||
| Abnormalities in brain structure and behavior in GSK-3alpha mutant mice | Q30485018 | ||
| Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour | Q30522548 | ||
| Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes | Q30530899 | ||
| Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease | Q33687072 | ||
| Association of GSK3B with Alzheimer disease and frontotemporal dementia | Q33737139 | ||
| Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo | Q33771431 | ||
| Mechanisms of tau-induced neurodegeneration | Q33859830 | ||
| The inflammatory response to double stranded DNA in endothelial cells is mediated by NFκB and TNFα | Q33911092 | ||
| Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. | Q34074409 | ||
| Long-term depression in the CNS. | Q34121481 | ||
| Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice | Q34449486 | ||
| Regulation of GABAergic synapse formation and plasticity by GSK3beta-dependent phosphorylation of gephyrin. | Q34472152 | ||
| Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency | Q34587440 | ||
| Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. | Q34691497 | ||
| Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity | Q34695519 | ||
| Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model | Q35104249 | ||
| Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta | Q35142950 | ||
| Protein phosphorylation and APP metabolism | Q35564758 | ||
| Role of tau protein in both physiological and pathological conditions. | Q35715199 | ||
| A pivotal role of GSK-3 in synaptic plasticity. | Q35757839 | ||
| The cell biology of synaptic plasticity. | Q35777989 | ||
| Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease | Q35839636 | ||
| Deciphering the molecular basis of memory failure in Alzheimer's disease | Q35902501 | ||
| GSK-3β and memory formation | Q35904141 | ||
| Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease | Q36012200 | ||
| Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies | Q36526315 | ||
| Glycogen synthase kinase-3--an overview of an over-achieving protein kinase | Q36651778 | ||
| The GSK3 hypothesis of Alzheimer's disease | Q37035378 | ||
| Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? | Q37053949 | ||
| The role of GSK-3 in synaptic plasticity. | Q37098587 | ||
| A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases | Q37274100 | ||
| Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders | Q37501675 | ||
| GSK3: a possible link between beta amyloid peptide and tau protein. | Q37603624 | ||
| Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies | Q37606284 | ||
| GSK-3 is a master regulator of neural progenitor homeostasis | Q37670059 | ||
| Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. | Q37779109 | ||
| Recent developments in tau-based therapeutics for neurodegenerative diseases | Q37813731 | ||
| Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease | Q37824813 | ||
| Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies | Q37946881 | ||
| New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. | Q37978196 | ||
| Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. | Q38674158 | ||
| Functional significance of glycogen synthase kinase-3 regulation by serotonin | Q38887848 | ||
| Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein | Q39289700 | ||
| Propagation of tau misfolding from the outside to the inside of a cell. | Q39873721 | ||
| Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease | Q39920144 | ||
| Extracellular tau is toxic to neuronal cells. | Q40242845 | ||
| Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate | Q40260863 | ||
| GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. | Q40470623 | ||
| Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event | Q40624453 | ||
| Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation | Q42130064 | ||
| Neurological functions of the masterswitch protein kinase - gsk-3. | Q42195030 | ||
| Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures | Q42556860 | ||
| Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation | Q42559938 | ||
| Calpain regulates N-terminal interaction of GSK-3β with 14-3-3ζ, p53 and PKB but not with axin | Q43435978 | ||
| Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta | Q44028713 | ||
| Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues | Q44277787 | ||
| Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice | Q44289387 | ||
| Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk | Q44560654 | ||
| Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila | Q44662134 | ||
| Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing | Q44915813 | ||
| GSK-3α/β kinases and amyloid production in vivo | Q45423209 | ||
| Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. | Q46097064 | ||
| Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism | Q46972415 | ||
| N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation | Q48136087 | ||
| The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice | Q48199895 | ||
| Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons | Q48221698 | ||
| Glycogen synthase kinase-3 inhibition is integral to long-term potentiation | Q48301898 | ||
| Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. | Q48433009 | ||
| Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. | Q48673331 | ||
| Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. | Q50524206 | ||
| Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. | Q51794745 | ||
| Chemical rescue of cleft palate and midline defects in conditional GSK-3beta mice. | Q51994753 | ||
| The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. | Q53246375 | ||
| P433 | issue | 5 | |
| P921 | main subject | synaptic plasticity | Q1551556 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 495-503 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes | |
| P478 | volume | 13 |
| Q47446543 | Adiponectin Attenuates Streptozotocin-Induced Tau Hyperphosphorylation and Cognitive Deficits by Rescuing PI3K/Akt/GSK-3β Pathway |
| Q58712518 | Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus |
| Q38556871 | Direct High Affinity Interaction between Aβ42 and GSK3α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease? |
| Q42689688 | Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease |
| Q27307787 | Intraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3. |
| Q38149943 | New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. |
| Q37053791 | Non-Catalytic Roles of Presenilin Throughout Evolution. |
| Q48469041 | Peripheral Administration of GSK-3β Antisense Oligonucleotide Improves Learning and Memory in SAMP8 and Tg2576 Mouse Models of Alzheimer's Disease |
| Q94551855 | Preventive Electroacupuncture Ameliorates D-Galactose-Induced Alzheimer's Disease-Like Pathology and Memory Deficits Probably via Inhibition of GSK3β/mTOR Signaling Pathway |
| Q21090465 | Protein phosphatase 2A dysfunction in Alzheimer's disease |
| Q30838734 | SK3 Channel Overexpression in Mice Causes Hippocampal Shrinkage Associated with Cognitive Impairments. |
| Q91823541 | The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment |
Search more.